Emerald Health Therapeutics' Pure Sunfarms JV Records Q3 Net Sales of $24.0 Million, 69% Gross Margin, 56% EBITDA Margin, Fourth Consecutive Quarter of Positive EBITDA, and $0.63/gram All-in Production Cost

Stock Information for Emerald Health Therapeutics Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Emerald Health Therapeutics Inc

CSE Bulletin: Delist - Emerald Health Therapeutics, Inc. (EMH)
Emerald Health Therapeutics and Skye Bioscience Close Plan of Arrangement
IIROC Trading Halt - EMH
Emerald Health Therapeutics and Skye Bioscience Announce Intended Closing Date of Plan of Arrangement
Emerald Health Therapeutics Announces Bridge Loan to Skye Bioscience and Provides Update on Merger
Skye Bioscience Stockholders Vote in Favor of Arrangement Agreement with Emerald Health Therapeutics, Inc.
Emerald Health Therapeutics, Inc. Reports 2022 Q2 Results
Emerald Health Therapeutics Receives Court Approval of Plan of Arrangement with Skye Bioscience

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.